{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:10:43Z","timestamp":1793171443355,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-65162-8","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T12:56:00Z","timestamp":1769000160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Neoadjuvant chemoradiotherapy plus sintilimab in proficient mismatch repair locally advanced rectal cancer with intermediate\/high-immunoscore (SILAR): a single-arm phase II trial"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-6411","authenticated-orcid":false,"given":"Xiaobin","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8932-4866","authenticated-orcid":false,"given":"Huashan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lishuo","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8789-821X","authenticated-orcid":false,"given":"Ziwei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangling","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghua","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanzhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuli","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5200-3997","authenticated-orcid":false,"given":"Yanxin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7062-8280","authenticated-orcid":false,"given":"Liang","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"65162_CR1","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","volume":"24","author":"AM Holder","year":"2024","unstructured":"Holder, A. M. et al. Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. Nat. Rev. Cancer 24, 498\u2013512 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"65162_CR2","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi, M. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat. Med. 26, 566\u2013576 (2020).","journal-title":"Nat. Med."},{"key":"65162_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S2468-1253(21)00348-4","volume":"7","author":"H Hu","year":"2022","unstructured":"Hu, H. et al. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial. Lancet Gastroenterol. Hepatol. 7, 38\u201348 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"65162_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.6004\/jnccn.2022.7060","volume":"21","author":"BY Xiao","year":"2023","unstructured":"Xiao, B. Y. et al. Neoadjuvant immunotherapy leads to major response and low recurrence in localized mismatch repair-deficient colorectal cancer. J. Natl Compr. Cancer Netw. 21, 60\u201366.e65 (2023).","journal-title":"J. Natl Compr. Cancer Netw."},{"key":"65162_CR5","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek, A. et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N. Engl. J. Med. 386, 2363\u20132376 (2022).","journal-title":"N. Engl. J. Med."},{"key":"65162_CR6","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(18)30789-X","volume":"391","author":"F Pag\u00e8s","year":"2018","unstructured":"Pag\u00e8s, F. et al. International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 391, 2128\u20132139 (2018).","journal-title":"Lancet"},{"key":"65162_CR7","doi-asserted-by":"crossref","unstructured":"Marliot, F. et al. Analytical validation of the immunoscore and its associated prognostic value in patients with colon cancer. J. Immunother. Cancer 8, e000272 (2020).","DOI":"10.1136\/jitc-2019-000272"},{"key":"65162_CR8","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960\u20131964 (2006).","journal-title":"Science"},{"key":"65162_CR9","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","volume":"20","author":"D Bruni","year":"2020","unstructured":"Bruni, D., Angell, H. K. & Galon, J. The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy. Nat. Rev. Cancer 20, 662\u2013680 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"65162_CR10","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1158\/1078-0432.CCR-13-2830","volume":"20","author":"MG Anitei","year":"2014","unstructured":"Anitei, M. G. et al. Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin. Cancer Res. 20, 1891\u20131899 (2014).","journal-title":"Clin. Cancer Res."},{"key":"65162_CR11","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-20-0337","volume":"26","author":"C El Sissy","year":"2020","unstructured":"El Sissy, C. et al. A diagnostic biopsy-adapted immunoscore predicts response to neoadjuvant treatment and selects patients with rectal cancer eligible for a watch-and-wait strategy. Clin. Cancer Res. 26, 5198\u20135207 (2020).","journal-title":"Clin. Cancer Res."},{"key":"65162_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1200\/JCO.23.00586","volume":"42","author":"C El Sissy","year":"2024","unstructured":"El Sissy, C. et al. International validation of the immunoscore biopsy in patients with rectal cancer managed by a watch-and-wait strategy. J. Clin. Oncol. 42, 70\u201380 (2024).","journal-title":"J. Clin. Oncol."},{"key":"65162_CR13","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1158\/1078-0432.CCR-19-3728","volume":"26","author":"A Cercek","year":"2020","unstructured":"Cercek, A. et al. Mismatch repair-deficient rectal cancer and resistance to neoadjuvant chemotherapy. Clin. Cancer Res. 26, 3271\u20133279 (2020).","journal-title":"Clin. Cancer Res."},{"key":"65162_CR14","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509\u20132520 (2015).","journal-title":"N. Engl. J. Med."},{"key":"65162_CR15","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","volume":"22","author":"T Conroy","year":"2021","unstructured":"Conroy, T. et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 22, 702\u2013715 (2021).","journal-title":"Lancet Oncol."},{"key":"65162_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","volume":"22","author":"RR Bahadoer","year":"2021","unstructured":"Bahadoer, R. R. et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 22, 29\u201342 (2021).","journal-title":"Lancet Oncol."},{"key":"65162_CR17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/jamasurg.2023.7996","volume":"159","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. Total neoadjuvant therapy with PD-1 blockade for high-risk proficient mismatch repair rectal cancer. JAMA Surg. 159, 529\u2013537 (2024).","journal-title":"JAMA Surg."},{"key":"65162_CR18","unstructured":"Xia, F. et al. Randomized phase II trial of immunotherapy-based total neoadjuvant therapy for proficient mismatch repair or microsatellite stable locally advanced rectal cancer (TORCH). J. Clin. Oncol. 42, Jco2302261 (2024)."},{"key":"65162_CR19","doi-asserted-by":"crossref","unstructured":"Xiao, W. W. et al. Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: a randomized clinical trial. Cancer Cell 42, 1570\u20131581.e4 (2024).","DOI":"10.1016\/j.ccell.2024.07.004"},{"key":"65162_CR20","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamaoncol.2021.1683","volume":"7","author":"OE Rahma","year":"2021","unstructured":"Rahma, O. E. et al. Use of total neoadjuvant therapy for locally advanced rectal cancer: initial results from the pembrolizumab arm of a phase 2 randomized clinical trial. JAMA Oncol. 7, 1225\u20131230 (2021).","journal-title":"JAMA Oncol."},{"key":"65162_CR21","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.1158\/1078-0432.CCR-22-3915","volume":"29","author":"A Oaknin","year":"2023","unstructured":"Oaknin, A. et al. Safety, efficacy, and biomarker analyses of dostarlimab in patients with endometrial cancer: interim results of the phase I GARNET study. Clin. Cancer Res. 29, 4564\u20134574 (2023).","journal-title":"Clin. Cancer Res."},{"key":"65162_CR22","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.1200\/JCO.2016.66.6198","volume":"34","author":"Y Deng","year":"2016","unstructured":"Deng, Y. et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase III trial. J. Clin. Oncol. 34, 3300\u20133307 (2016).","journal-title":"J. Clin. Oncol."},{"key":"65162_CR23","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1200\/JCO.19.00308","volume":"37","author":"E Fokas","year":"2019","unstructured":"Fokas, E. et al. Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO\/ARO\/AIO-12. J. Clin. Oncol. 37, 3212\u20133222 (2019).","journal-title":"J. Clin. Oncol."},{"key":"65162_CR24","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/annonc\/mdy551","volume":"30","author":"KM Heinhuis","year":"2019","unstructured":"Heinhuis, K. M. et al. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann. Oncol. 30, 219\u2013235 (2019).","journal-title":"Ann. Oncol."},{"key":"65162_CR25","doi-asserted-by":"crossref","unstructured":"Lin, Z. et al. Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer. J. Immunother. Cancer 9, e003554 (2021).","DOI":"10.1136\/jitc-2021-003554"},{"key":"65162_CR26","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1158\/1078-0432.CCR-21-3213","volume":"28","author":"H Bando","year":"2022","unstructured":"Bando, H. et al. Preoperative chemoradiotherapy plus nivolumab before surgery in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer. Clin. Cancer Res. 28, 1136\u20131146 (2022).","journal-title":"Clin. Cancer Res."},{"key":"65162_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115428","volume":"222","author":"A Shamseddine","year":"2025","unstructured":"Shamseddine, A. et al. Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced microsatellite stable rectal adenocarcinoma: the Averectal study. Eur. J. Cancer 222, 115428 (2025).","journal-title":"Eur. J. Cancer"},{"key":"65162_CR28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41392-024-01762-y","volume":"9","author":"Z Yang","year":"2024","unstructured":"Yang, Z. et al. Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study. Signal Transduct. Target. Ther. 9, 56 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"65162_CR29","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.ijrobp.2024.10.004","volume":"121","author":"Q Zeng","year":"2025","unstructured":"Zeng, Q. et al. Prognostic and predictive value of a modified diagnostic biopsy-adapted immunoscore in patients with rectal cancer after neoadjuvant treatment: a translational study from the STELLAR trial. Int. J. Radiat. Oncol. Biol. Phys. 121, 640\u2013650 (2025).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"65162_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104102","volume":"10","author":"R Zhao","year":"2025","unstructured":"Zhao, R. et al. Integrating radiomics, pathomics, and biopsy-adapted immunoscore for predicting distant metastasis in locally advanced rectal cancer. ESMO Open 10, 104102 (2025).","journal-title":"ESMO Open"},{"key":"65162_CR31","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1200\/JCO.23.02449","volume":"42","author":"Z Gao","year":"2024","unstructured":"Gao, Z., Zhu, Z. & Li, K. Immunoscore biopsy in patients with rectal cancer managed by a watch-and-wait strategy. J. Clin. Oncol. 42, 1088 (2024).","journal-title":"J. Clin. Oncol."},{"key":"65162_CR32","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1245\/s10434-018-6462-1","volume":"25","author":"MR Weiser","year":"2018","unstructured":"Weiser, M. R. AJCC 8th edition: colorectal cancer. Ann. Surg. Oncol. 25, 1454\u20131455 (2018).","journal-title":"Ann. Surg. Oncol."},{"key":"65162_CR33","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/S0140-6736(86)92612-7","volume":"2","author":"P Quirke","year":"1986","unstructured":"Quirke, P., Durdey, P., Dixon, M. F. & Williams, N. S. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet 2, 996\u2013999 (1986).","journal-title":"Lancet"},{"key":"65162_CR34","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","volume":"34","author":"FS Hodi","year":"2016","unstructured":"Hodi, F. S. et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J. Clin. Oncol. 34, 1510\u20131517 (2016).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65162-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65162-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65162-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:11:24Z","timestamp":1769213484000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65162-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["65162"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-65162-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"25 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"772"}}